Search clinical trials for: Brolucizumab

Total 47 results

Novartis Pharmaceuticals

Not yet recruiting

Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.

Diabetic Macular Edema
Novartis Pharmaceuticals

Terminated

Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice (BESRA)

Neovascular Age-related Macular Degeneration

United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema (BLUE SKY)

Diabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD)

Germany
Novartis Pharmaceuticals

Active, not recruiting

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal (BLUESKY-PT)

Neovascular Age-related Macular Degeneration (nAMD)

Portugal
Novartis Pharmaceuticals

Recruiting

Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

Neovascular Age-related Macular Degeneration

United Arab Emirates
Novartis Pharmaceuticals

Withdrawn

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) (PEREGRINE)

Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (FALCON)

Age-related Macular Degeneration

Germany, Switzerland
Novartis Pharmaceuticals

Active, not recruiting

Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection

Diabetic Macular Edema

Japan
Novartis Pharmaceuticals

Recruiting

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Neovascular Age-related Macular Degeneration

Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Neovascular Age Related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

Neovascular Age-related Macular Degeneration

Japan
Alcon Research

Completed

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration
Yeungnam University College of Medicine
Novartis

Not yet recruiting

Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy (PABLO)

Age-Related Macular Degeneration | Pachychoroid Neovasculopathy
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)

Age-related Macular Degeneration (AMD)

United States
Novartis Pharmaceuticals

Completed

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Age-related Macular Degeneration (AMD)

United States
Benha University

Unknown

BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Dystrophy, Retinal

United Arab Emirates
Novartis Pharmaceuticals

Completed

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration (SWIFT)

Neovascular Age-Related Macular Degeneration

France
Novartis Pharmaceuticals

Completed

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration (OCTOPUS)

Neovascular Age Related Macular Degeneration

France
Novartis Pharmaceuticals

Recruiting

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PROUD)

Macular Polypoidal Choroidal Vasculopathy (PCV)

Korea, Republic of
Novartis Pharmaceuticals

Completed

Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion

Intraocular Inflammation | Retinal Vascular Occlusion

Switzerland
Novartis Pharmaceuticals

Completed

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (TALON Ext)

Neovascular Age-related Macular Degeneration

United States, Czechia, Italy, Taiwan, Australia, Israel, Belgium, France, Spain, Germany, Korea, Republic of, Portugal, Sweden, Netherlands, Malaysia, Switzerland
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy (CONDOR)

Proliferative Diabetic Retinopathy

China, India, Japan, Russian Federation, Turkey, Canada, United States, Australia, Korea, Republic of, Brazil, Philippines, Puerto Rico, Taiwan, Argentina, Chile, Mexico
Novartis Pharmaceuticals

Completed

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Wet Macular Degeneration

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. (IMAGINE)

Neovascular Age-related Macular Degeneration

Italy
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration (nAMD)

India
Benha University

Recruiting

BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema

Macular Edema

United Arab Emirates
Universitaire Ziekenhuizen KU Leuven

Active, not recruiting

Beovu Experience UZ Leuven (BEL)

Age-Related Macular Degeneration

Belgium
Vista Klinik
Novartis

Terminated

Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept (ROBIN)

Neovascular Age-related Macular Degeneration

Switzerland
The University of Hong Kong

Recruiting

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

Age-Related Macular Degeneration

Hong Kong
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KESTREL)

Diabetic Macular Edema

United States, Austria, Japan, Australia, Spain, Canada, Israel, Netherlands, Italy, United Kingdom, Portugal, Colombia, Puerto Rico, Argentina
Novartis Pharmaceuticals

Completed

To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema (KINGLET)

Diabetic Macular Edema

China
Novartis Pharmaceuticals

Withdrawn

Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (BUZZARD)

Diabetic Macula Edema
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)

Diabetic Macular Edema

United States, Hungary, Israel, Slovakia, Puerto Rico
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KITE)

Diabetic Macular Edema

Czechia, India, Russian Federation, Taiwan, Turkey, Lebanon, Denmark, Estonia, France, Germany, Hungary, Korea, Republic of, Latvia, Lithuania, Bulgaria, Norway, Belgium, Malaysia, Sweden, Slovakia, Singapore, Poland, Switzerland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Novartis Pharmaceuticals

Completed

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (RAZORBILL)

Neovascular Age-Related Macular Degeneration

Spain, Italy, Germany, Canada, Ireland
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)

Age-Related Macular Degeneration

United States, Puerto Rico
Berner Augenklinik
medignition AG

Enrolling by invitation

Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD (SPARROW)

Wet Age-related Macular Degeneration

Switzerland
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
Astra USA

Completed

Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease

Gastrointestinal Diseases | HIV Infections

United States
Alcon Research

Completed

Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 (HARRIER)

Choroidal Neovascularization | Neovascular Age-Related Macular Degeneration
Alcon Research

Completed

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 (HAWK)

Choroidal Neovascularization | Neovascular Age-Related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

Neovascular Age-related Macular Degeneration

United States, Puerto Rico
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

Branch Retinal Vein Occlusion

China, Austria, Czechia, Russian Federation, Taiwan, United Kingdom, Canada, Japan, United States, France, Israel, Germany, Italy, Hong Kong, Spain, Denmark, Slovakia, Puerto Rico, Switzerland
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)

Central Retinal Vein Occlusion

China, Czechia, Germany, Russian Federation, Turkey, United States, Australia, Canada, Spain, United Kingdom, Thailand, Israel, Netherlands, Italy, Hungary, France, Greece, Puerto Rico, Malaysia, Japan
Faculty Hospital Kralovske Vinohrady

Withdrawn

Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation (BEY-RAP)

Wet Macular Degeneration

Czechia

3

Subscribe